Pendal Group’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$1.85M Sell
19,898
-94,511
-83% -$9.12M 0.02% 220
2022
Q3
$10.9M Buy
114,409
+80,650
+239% +$7.98M 0.11% 106
2022
Q2
$3.13M Buy
33,759
+24,740
+274% +$2.41M 0.03% 168
2022
Q1
$913K Sell
9,019
-15,549
-63% -$1.63M 0.01% 345
2021
Q4
$2.53M Buy
24,568
+10,423
+74% +$963K 0.02% 215
2021
Q3
$1.2M Sell
14,145
-25,858
-65% -$2.17M 0.01% 300
2021
Q2
$3.34M Buy
40,003
+32,750
+452% +$2.68M 0.03% 185
2021
Q1
$546K Sell
7,253
-15,575
-68% -$1.13M 0.01% 396
2020
Q4
$1.56M Sell
22,828
-19,062
-46% -$1.24M 0.02% 242
2020
Q3
$2.45M Buy
41,890
+258
+0.6% +$16.1K 0.03% 151
2020
Q2
$2.71M Buy
+41,632
New +$2.62M 0.04% 143
2019
Q2
Sell
-1,097
Closed -$59.2K 439
2019
Q1
$59.2K Buy
+1,097
New +$67.7K ﹤0.01% 425
2018
Q1
Sell
-129,423
Closed -$9.38M 470
2017
Q4
$9.38M Buy
129,423
+123,186
+1,975% +$8.96M 0.12% 122
2017
Q3
$507K Buy
6,237
+5,611
+896% +$444K 0.01% 374
2017
Q2
$50.4K Buy
+626
New +$49.4K ﹤0.01% 450

Other funds holding CVS

Pendal Group's CVS Position: Q4 2022 in Review

Pendal Group reduced its CVS Health (CVS) stake by 83% in Q4 2022, selling an estimated $9.12M and leaving 19,898 shares worth $1.85M. The position accounts for 0.02% of the portfolio, ranked #220.

Pendal Group first reported a position in CVS in Q2 2017 and has held it in 15 quarters since. The position peaked at $10.9M in Q3 2022. 2,405 funds tracked by Wall St. Rank hold CVS as of Q4 2022.

  • Pendal Group held 19,898 shares of CVS Health worth $1.85M as of Q4 2022.
  • Pendal Group sold 94,511 CVS Health shares in Q4 2022, an estimated $9.12M.
  • CVS Health made up 0.02% of Pendal Group's portfolio in Q4 2022, its #220 holding.
  • Pendal Group first reported a position in CVS Health in Q2 2017 and has held it in 15 quarters since.
  • Pendal Group's CVS Health position peaked at $10.9M in Q3 2022.
  • 2,405 funds tracked by Wall St. Rank held CVS Health as of Q4 2022.

Based on Pendal Group's 13F filing for Q4 2022, filed 19 Jan 2023.